cyclophosphamide

  1. J

    Review High-dose Cyclophosphamide Without Stem Cell Rescue in Autoimmune Diseases: A Systematic Review Carvalho 2024

    Abstract High-dose cyclophosphamide without stem cell rescue is a radical therapy for refractory autoimmune diseases. The objective was to review the results of high-dose cyclophosphamide without stem cell rescue in autoimmune diseases. PubMed, Scielo, and Embase databases were systematically...
  2. SNT Gatchaman

    Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in [ME/CFS], 2024, Rekeland, Fluge, Mella et al.

    Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Ingrid G. Rekeland; Kari Sørland; Lisbeth Lykke Neteland; Alexander Fosså; Kine Alme; Kristin Risa; Olav Dahl; Karl J. Tronstad; Olav Mella; Øystein...
  3. Dolphin

    Thesis Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Clinical trials, medical treatment and pathomechanisms, 2024, Rekeland

    https://bora.uib.no/bora-xmlui/handle/11250/3127770 Source: University of Bergen Date: May 2, 2024 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Clinical trials, medical treatment and pathomechanisms ------------------------------------------------------------ Ingrid Gurvin...
  4. John Mac

    Reduced endothelial function in ME/CFS - results from open-label cyclophosphamide intervention study Fluge & Mella 2021

    Full title: Reduced endothelial function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - results from open-label cyclophosphamide intervention study Provisionally accepted https://www.frontiersin.org/articles/10.3389/fmed.2021.642710/abstract
  5. Kalliope

    Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study - 2020 - Rekeland, Mella, Fluge et al

    published in frontiers in Medicine - Family Medicine and Primary Care Results: The overall response rate by Fatigue score was 55.0% (22 of 40 patients). Fatigue score and other outcome variables showed significant improvements compared to baseline. The SF-36 Physical Function score increased...
  6. J

    Inhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response

    https://www.cell.com/neuron/pdfExtended/S0896-6273(19)30733-0 Used cyclophosphamide to treat autism symptoms in mice by reducing brain inflammation.
  7. Cheshire

    Øystein Fluge and Olav Mella's ME/CFS research

    Rituximab (RituxME) Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series Øystein Fluge and Olav Mella BMC Neurology 2009 Link to article Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in...
Back
Top Bottom